Preclinical safety assessment in therapeutic genome editing

Roberto Nitsch

Director of the Gene Therapy Safety, AstraZeneca

“There is a clear need in this field for better and more translatable preclinical models. Using humanized models provides an environment in which human cells behave more like they would in the body...”

On February 23rd 2023, David McCall, Editor, Cell & Gene Therapy Insights, talked to Roberto Nitsch, Director of the Gene Therapy Safety at AstraZeneca, about his work in the space of genome editing nonclinical safety assessment and model development. This Viewpoint article is based on that interview.

Please enter your email to access content Read now